Who Supplies Amoxicillin to India from LITHUANIA

Importing finished pharmaceutical formulations containing Amoxicillin into India requires compliance with regulations set by the Central Drugs Standard Control Organisation (CDSCO). The importer must obtain a valid Drug Import License from the Directorate General of Foreign Trade (DGFT). The product must be registered with CDSCO, which involves submitting Form 40 or 41, depending on the product type. The registration process includes providing a Certificate of Pharmaceutical Product (CoPP), stability data (preferably ICH Zone IV), and a No Objection Certificate (NOC) from the manufacturer. The timeline for import drug registration varies but typically ranges from 6 to 12 months. For Amoxicillin formulations under HS Code 30041030, specific requirements include demonstrating compliance with the Indian Pharmacopoeia standards and providing a Certificate of Analysis (CoA) for each batch.

Upon arrival in India, each batch of Amoxicillin formulations must undergo quality testing at a CDSCO-approved laboratory. This testing ensures that the product meets the standards set by the Indian Pharmacopoeia. A Certificate of Analysis (CoA) is required for each batch, detailing the product's composition, purity, and compliance with specified standards. Stability data, preferably from ICH Zone IV studies, must be provided to demonstrate the product's shelf-life under Indian climatic conditions. Port inspections by customs drug inspectors are conducted to verify the authenticity and quality of the imported products.

In January 2026, the Indian government imposed a Minimum Import Price (MIP) on key antibiotics, including Amoxicillin trihydrate. The MIP for Amoxicillin trihydrate is set at ₹2,733 per kg, effective from January 29, 2026, for one year. This measure aims to curb low-cost imports, particularly from China, and protect domestic pharmaceutical manufacturing investments. The Production-Linked Incentive (PLI) scheme, introduced to boost domestic manufacturing, may impact the volume of finished formulation imports, as it incentivizes local production. Bilateral agreements between India and Lithuania have not been reported to specifically address pharmaceutical trade facilitation.

India imports finished Amoxicillin formulations to meet domestic demand for various dosage forms, including tablets, capsules, syrups, and injections. While India has a robust pharmaceutical manufacturing sector, certain patented or specialized formulations not produced domestically necessitate imports. The market size for Amoxicillin formulations in India is substantial, with a total export market of $610.1 million across 633 exporters to 161 countries. The demand for Amoxicillin imports is influenced by factors such as disease prevalence, treatment protocols, and the availability of specific formulations.

The Basic Customs Duty (BCD) on Amoxicillin formulations under HS Code 30041030 is 10%. A Social Welfare Surcharge (SWS) of 10% on BCD is applicable, resulting in an effective duty rate of 11%. Integrated Goods and Services Tax (IGST) of 12% is levied on the import value. Additional charges may include port handling fees, customs broker charges, and other applicable levies. The Minimum Import Price (MIP) of ₹2,733 per kg for Amoxicillin trihydrate, effective from January 29, 2026, aims to curb low-cost imports and protect domestic manufacturing. Exemptions or preferential duty rates may apply under specific trade agreements or for certain product categories.

Lithuania's pharmaceutical industry is known for producing high-quality Amoxicillin formulations, which are competitive in the Indian market. The country's adherence to Good Manufacturing Practices (GMP) and compliance with international standards make its products attractive to Indian importers. While other suppliers, such as China, Germany, and the United States, also export Amoxicillin formulations to India, Lithuania's focus on quality and regulatory compliance provides a competitive edge. Lithuania's share in the Indian market for Amoxicillin formulations is growing, reflecting increasing trust in its pharmaceutical exports.

India imports Amoxicillin formulations from Lithuania due to the country's reputation for high-quality pharmaceutical products. Lithuanian manufacturers adhere to stringent Good Manufacturing Practices (GMP) and international standards, ensuring product safety and efficacy. Specific formulations, such as certain dosage forms or combinations, may not be produced domestically, necessitating imports. Lithuania's competitive pricing and reliable supply chain further enhance its attractiveness as a sourcing destination.

When compared to other origins like China, Germany, and the United States, Lithuania offers a unique combination of quality and compliance. While China may offer lower prices, concerns about quality and regulatory compliance can be a deterrent. Germany and the United States provide high-quality products but at higher costs. Lithuania's balance of quality, compliance, and cost positions it favorably in the Indian market.

Potential risks for Indian importers include reliance on a single supplier, currency fluctuations, regulatory changes, and shipping disruptions. Diversifying the supplier base and maintaining adequate inventory levels can mitigate these risks. Monitoring currency exchange rates and staying informed about regulatory updates are also crucial for effective risk management.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain buffer stocks to manage supply chain disruptions.
3. 3Payment Terms: